Latest line of therapy and treatment resulting in CR, with imaging and MRD negative for more than or equal to 5 years
| . | n (%) . | Quadruplet∗ . | Triplet . | Doublet . | ASCT . |
|---|---|---|---|---|---|
| Last line of therapy | |||||
| First | 44 (57.9) | 9 (20.5) | 33 (75.0) | 2 (4.5) | 27 (61.4) |
| Second | 21 (27.6) | 3 (14.2) | 17 (81.0) | 1 (4.8) | 7 (33.3) |
| Third or later | 11 (14.5) | 2 (18.2) | 4 (36.4) | 4 (36.4) | 5 (45.5) |
| Latest line of therapy type | |||||
| PI-containing | 65 (85.5) | ||||
| IMiD-containing | 66 (86.8) | ||||
| Anti-CD38 mAb-containing | 28 (36.8) |
| . | n (%) . | Quadruplet∗ . | Triplet . | Doublet . | ASCT . |
|---|---|---|---|---|---|
| Last line of therapy | |||||
| First | 44 (57.9) | 9 (20.5) | 33 (75.0) | 2 (4.5) | 27 (61.4) |
| Second | 21 (27.6) | 3 (14.2) | 17 (81.0) | 1 (4.8) | 7 (33.3) |
| Third or later | 11 (14.5) | 2 (18.2) | 4 (36.4) | 4 (36.4) | 5 (45.5) |
| Latest line of therapy type | |||||
| PI-containing | 65 (85.5) | ||||
| IMiD-containing | 66 (86.8) | ||||
| Anti-CD38 mAb-containing | 28 (36.8) |
ASCT, autologous stem cell transplant; IMiD, immunomodulatory drug; mAb, monoclonal antibody; PI, proteasome inhibitor.
Quadruplet therapy refers to a combination of proteasome inhibitor, immunomodulatory drug, monoclonal antibody, and steroid. Triplet therapy and doublet therapy refer to combination with any 3 or 2 of the aforesaid, respectively.